Intrapulmonal nintedanib distribution in fibrotic interstitial lung disease patients: drug concentrations in lung explantates

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON21428

Enrollment

Registered

2020-09-16

Start date

2020-08-01

Completion date

Unknown

Last updated

2024-02-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Interstitial lung disease

Interventions

None listed

Eligibility

Inclusion criteria

Inclusion criteria: Patients treated with nintedanib until lung transplantation

Exclusion criteria

Exclusion criteria: Unwilling to sign informed consent

Design outcomes

Primary

Measure	Time frame
Penetration rate of nintedanib in different types of lung tissue.	—

Secondary

Measure	Time frame
Variability in nintedanib concentrations	—

Contacts

Public ContactG.D. Marijn Veerman

Erasmus MC

g.veerman@erasmusmc.nl0641531792

Outcome results